UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Sep

    05

    The Legacy Continues: Celebrating Two Decades of the UCB Family Epilepsy Scholarship ProgramTM

    Read More

    Oct

    31

    NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

    Read More

    Sep

    05

    Announcing the 2023 UCB Family Epilepsy Scholarship Winners

    Read More

    Aug

    17

    UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

    Read More

    Aug

    16

    How Winners of the UCB Family Epilepsy Scholarship Prepare to Go Back to School

    As students and parents prepare for a new school year, there can be a lot of stress  – from meeting new teachers and preparing for classes, to financial assistance and making new friends. For people living with epilepsy and their caregivers, the stress and worry surrounding back-to-school preparation is compounded.

    Read More

    Jun

    13

    UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups

    Read More

    Mar

    28

    FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

    Read More

    Mar

    07

    UCB Completes Acquisition of Zogenix, Inc.

    Read More

    Jan

    19

    UCB to acquire Zogenix

    Read More

    Aug

    30

    UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

    Read More

    © 2009 - 2026 UCB, Inc. Atlanta. All rights reserved. 
    Last updated: March 2026